Tumor-associated antigen presented by dendritic cell

The term **"tumor-associated antigens presented by dendritic cell"** does not refer to a single molecule or canonical therapeutic target. Instead, it describes a class of **tumor-derived proteins or peptides** that are captured and processed by **dendritic cells (DCs)**—the body's most efficient professional antigen-presenting cells[1][2][3][8]. These antigens are internalized from tumor cells, processed into short peptides, and loaded onto major histocompatibility complex (MHC) molecules on the surface of DCs[5]. The resulting MHC-peptide complexes are then recognized by T-cells in lymphoid organs, initiating anti-tumor immune responses. Dendritic cells play a central role in cancer immunology because they bridge innate and adaptive immunity. They present both extracellularly derived antigens via MHC class II molecules to CD4+ helper T-cells and intracellular/cross-presented antigens via MHC class I molecules to CD8+ cytotoxic T-cells[1][2][5]. This cross-presentation is crucial for generating effective anti-tumor cytolytic responses. In cancer therapy research—including vaccine development—DCs are often engineered ex vivo with specific tumor-associated antigens before being reintroduced into patients as cellular vaccines[1][5]. Because "tumor-associated antigens presented by dendritic cell" refers broadly to any such peptide-MHC complex rather than one defined protein/receptor/target gene product, it is not considered a canonical therapeutic target like an enzyme or receptor. Instead, it represents an immunological process essential for anti-tumor immunity but too generic for structured drug-target mapping. If you need information about specific well-characterized tumor-associated antigens (e.g., NY-ESO-1, MAGE-A3) or about particular receptors on dendritic cells involved in this process (e.g., DEC205/CD205), those would be more appropriate entries for structured data extraction. > Dendritic cells initiate anti-tumor immunity through recognition and capture of tumor-associated antigens followed by their presentation on MHC molecules—a critical step in activating both helper and cytotoxic T-cell responses against tumors[1][2][3]. In summary: This entry is *too broad*—it describes an important biological phenomenon rather than a discrete molecular entity suitable as a canonical drug target.

Other names

Tumor antigen presented by dendritic cellTAA presented by DCDendritic cell-presented tumor antigen